Vaccine Formulation and Adjuvants are crucial components in the development of effective vaccines, enhancing their immunogenicity and efficacy. Vaccine formulation refers to the precise composition and preparation of vaccines, including the selection of antigens, adjuvants, stabilizers, and delivery systems. The primary goal of vaccine formulation is to stimulate a robust and long-lasting immune response against specific pathogens while ensuring safety and stability. This involves identifying and selecting antigens that are capable of eliciting an immune response and formulating them in a manner that enhances their stability and immunogenicity.
Adjuvants are substances added to vaccines to enhance the immune response to antigens. They work by activating and modulating the innate immune system, increasing antigen presentation and promoting the production of antibodies and memory cells. Common adjuvants include aluminum salts, oil-in-water emulsions, and saponins. The selection of adjuvants depends on various factors, including the type of antigen, the desired immune response, and safety considerations. Adjuvants can improve vaccine efficacy by reducing the amount of antigen required per dose, allowing for dose sparing and increasing the duration and magnitude of the immune response.
In addition to adjuvants, vaccine formulation may also include stabilizers, preservatives, and excipients to enhance vaccine stability, shelf-life, and safety. Stabilizers help protect vaccines from degradation during storage and transport, while preservatives prevent microbial growth and contamination. Excipients such as buffers and pH adjusters maintain the pH and osmolarity of the vaccine formulation, ensuring compatibility with the body's tissues.
Title : A promising novel approach to DNA vaccines
Khursheed Nadeem Anwer, IMUNON, United States
Title : Nanoscopic SubATVax™ adjuvanted vaccines against influenza A types H3N2, H1N1 and influenza type B for subcutaneous administration
David Craig Wright, D4 Labs, LLC, United States
Title : The importance of post-marketing surveillance and real-world data for a product to be successful
Regina Au, BioMarketing Insight, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Commensal bacteria drive B-cell lymphomagenesis in the setting of innate immunodeficiency
Ping Xie, Rutgers University, United States
Title : The role of immunity in the pathogenesis of SARS-COV-2 and in the protection generated by COVID-19 in different age groups
Ahmed Abdulazeez, BHRUT Trust, United Kingdom
Title : Establishing a platform method for physical appearance assessment of new parenteral pharmaceuticals
Ying Wan, Merck & Co., United States
Title : Evaluating the immunogenic impact of process impurities in mRNA vaccine production: Establishing integrated control strategies and specifications
Jesse Kuiper, Merck Research Laboratories, United States
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Advances in vaccines: Revolutionizing disease prevention
Delia Teresa Sponza, Dokuz Eylul University, Turkey